V
Vertex Pharmaceuticals Incorporated (VRTX)
NMS – Real vaqt narxi. Valyuta: USD
448.29
+13.12 (3.01%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
448.29
+13.12 (3.01%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Vertex Pharmaceuticals Incorporated Qo'shma Shtatlar, Yevropa va xalqaro miqyosda faoliyat yurituvchi biotexnologiya kompaniyasidir. Kompaniya noyob bozorlarga, jumladan, kistoz fibroz (KF), o'roq hujayrali anemiya (OHA), qon quyishga bog'liq beta-talassemiya (QBBT) va o'tkir og'riq kabi jiddiy kasalliklarga chalingan odamlar uchun transformativ dorilarni taklif etadi. Kompaniya 2 yosh va undan katta, kamida bitta F508del mutatsiyasiga ega KF bilan kasallangan odamlar uchun TRIKAFTA/KAFTRIO; 6 yosh va undan katta KF bilan kasallangan odamlar uchun ALYFTREK; 6 yosh va undan katta KF bemorlarini davolash uchun SYMDEKO/SYMKEVI; 1 yosh va undan katta KF bemorlari uchun ORKAMBI; va ivakaftor bilan 1 oylik va undan katta KF bemorlarini davolash uchun KALYDECO dorilarini sotadi. Kompaniya shuningdek OHA va QBBTni davolash uchun CASGEVY; kattalardagi o'tkir og'riqni davolash uchun JOURNAVX; KFning asosiy sababini davolashga mo'ljallangan, 1/2 bosqichli klinik sinovda bo'lgan CFTR mRNA terapevtik vositasi VX-522; APOL1 vositali buyrak kasalligini davolash uchun, 2-bosqichli yakka tadqiqotda bo'lgan inaksaplin; 1-tipli diabetni davolash uchun VX-264; miyotonik distrofiyaning 1-turi uchun VX-670; va autosomal dominant polikistik buyrak kasalligini davolash uchun kichik molekulali korrektori VX-407ni ishlab chiqadi. Kompaniya o'z mahsulotlarini asosan maxsus dorixonalar va distribyutorlarga, ulgurji sotuvchilarga, chakana dorixonalar, shifoxonalar va klinikalarga sotadi. Vertex Pharmaceuticals Incorporated 1989 yilda tashkil etilgan va shtab-kvartirasi Boston, Massachusetsda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Carmen Bozic M.D. | Executive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer |
| Dr. Jeffrey Marc Leiden M.D., Ph.D. | Executive Chairman |
| Dr. Mark Bunnage D.Phil | Executive VP & Chief Scientific Officer |
| Dr. Ourania Tatsis Ph.D. | Executive VP and Chief Regulatory & Quality Officer |
| Dr. Reshma Kewalramani FASN, M.D. | CEO, President & Director |
| Mr. Amit K. Sachdev J.D. | Executive VP & Chief Patient and External Affairs Officer |
| Mr. Charles F. Wagner Jr. | Executive VP, COO & CFO |
| Ms. Joy Liu J.D. | EVP, Chief Legal Officer & Corporate Secretary |
| Ms. Kristen C. Ambrose CPA | Senior VP & Chief Accounting Officer |
| Ms. Susie Lisa C.F.A. | Senior Vice President of Investor Relations |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-05 | 10-Q | vrtx-20260331.htm |
| 2026-05-04 | 8-K | vrtx-20260504.htm |
| 2026-04-29 | DEFA14A | a2026vertexapril.htm |
| 2026-04-29 | 8-K | vrtx-20260428.htm |
| 2026-04-02 | DEFA14A | a2026vertexna.htm |
| 2026-03-31 | 8-K | vrtx-20260331.htm |
| 2026-02-13 | 10-K | vrtx-20251231.htm |
| 2026-02-12 | 8-K | vrtx-20260212.htm |
| 2025-11-04 | 10-Q | vrtx-20250930.htm |
| 2025-11-03 | 8-K | vrtx-20251103.htm |